BiotechTube

Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%

Phase 3Active
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Actinic Keratosis

Conditions

Actinic Keratosis

Trial Timeline

Nov 29, 2025 → Apr 1, 2027

NCT ID
NCT07144852

About Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%

Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20% is a phase 3 stage product being developed by Sun Pharmaceutical for Actinic Keratosis. The current trial status is active. This product is registered under clinical trial identifier NCT07144852. Target conditions include Actinic Keratosis.

What happened to similar drugs?

7 of 20 similar drugs in Actinic Keratosis were approved

Approved (7) Terminated (1) Active (13)
✅fluorouracil cream 0.5%SanofiApproved
✅Imiquimod + DiclofenacViatrisApproved
✅Imiquimod + DiclofenacViatrisApproved
✅Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelAlmirallApproved
✅Tirbanibulin 2.5 mg ointmentAlmirallApproved
✅TirbanibulinAlmirallApproved
✅Ameluz 10% Topical GelBiofronteraApproved

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07144852Phase 3Active
NCT07144345Phase 3Active

Competing Products

20 competing products in Actinic Keratosis

See all competitors
ProductCompanyStageHype Score
Low dose DFD07 once daily + High dose DFD07 once daily + High dose DFD07 twice daily + Placebo twice dailyDr. Reddy's LaboratoriesPhase 2/3
35
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
44
Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical GelSun PharmaceuticalPhase 1
29
Imiquimod Topical Cream 3.75% + Zyclara® (imiquimod) Topical Cream 3.75% + Vehicle Topical CreamSun PharmaceuticalPhase 1
29
Imiquimod 5% manufactured by Taro + Aldara - Imiquimod 5% + Imiquimod Vehicle manufactured by TaroSun PharmaceuticalPhase 1
29
Investigational Treatment + Active comparatorNovartisPhase 2
35
KX01 ointment 1% + PlaceboPharmaEssentiaPhase 3
40
FluorouracilSanofiPhase 1/2
32
fluorouracil cream 0.5%SanofiApproved
43
Imiquimod + DiclofenacViatrisApproved
40
Imiquimod 5 % CreamViatrisPhase 2
32
ImiquimodViatrisPre-clinical
23
Aldara (Imiquimod)ViatrisPhase 3
37
Imiquimod + DiclofenacViatrisApproved
40
Placebo Gel + LAS41005 + LAS106521AlmirallPhase 3
34
5-fluorouracil/salicylic acid + VehicleAlmirallPhase 3
34
50 mg of KX2-391 Ointment 1% + 50 mg of KX2-391 Ointment 1%AlmirallPhase 2
29
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelAlmirallApproved
41
KX2-391 Ointment 1% + PlaceboAlmirallPhase 3
34
Tirbanibulin 2.5 mg ointmentAlmirallApproved
37